Nafcillin sodium - Generic Drug Details

What are the generic drug sources for nafcillin sodium and what is the scope of patent protection?

Nafcillin sodium is the generic ingredient in five branded drugs marketed by Wyeth Ayerst, Antibiotice, Apothecon, Eugia Pharma Speclts, Fresenius, Istituto Bio Ita Spa, Onesource Specialty, Sagent Pharms, Sandoz, Watson Labs Inc, Glaxosmithkline, and Baxter Hlthcare, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for nafcillin sodium. Twelve suppliers are listed for this compound.

Summary for nafcillin sodium

US Patents:	0
Tradenames:	5
Applicants:	12
NDAs:	23
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	1,760
What excipients (inactive ingredients) are in nafcillin sodium?	nafcillin sodium excipients list
DailyMed Link:	nafcillin sodium at DailyMed

Recent Clinical Trials for nafcillin sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all nafcillin sodium clinical trials

Pharmacology for nafcillin sodium

Drug Class

Penicillin-class Antibacterial

Medical Subject Heading (MeSH) Categories for nafcillin sodium

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for nafcillin sodium

J01CF	Beta-lactamase resistant penicillins
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for nafcillin sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sagent Pharms	NAFCILLIN SODIUM	nafcillin sodium	INJECTABLE;INJECTION	090582-001	Aug 24, 2012	AP	RX	No	No
Glaxosmithkline	NALLPEN	nafcillin sodium	INJECTABLE;INJECTION	061999-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs Inc	NAFCILLIN SODIUM	nafcillin sodium	INJECTABLE;INJECTION	062844-003	Oct 26, 1988		DISCN	No	No
Wyeth Ayerst	UNIPEN	nafcillin sodium	INJECTABLE;INJECTION	062717-001	Dec 16, 1986		DISCN	No	No
Istituto Bio Ita Spa	NAFCILLIN SODIUM	nafcillin sodium	INJECTABLE;INJECTION	090005-001	Apr 20, 2011	AP	RX	No	No
Sandoz	NAFCILLIN SODIUM	nafcillin sodium	INJECTABLE;INJECTION	062732-002	Dec 23, 1986		DISCN	No	No

Market Dynamics and Financial Trajectory for Nafcillin Sodium

Last updated: July 28, 2025

Introduction

Nafcillin sodium, a penicillinase-resistant penicillin, is a beta-lactam antibiotic primarily used to treat penicillinase-producing staphylococcal infections. Its molecular stability against beta-lactamase enzymes makes it a critical component in combating resistant bacterial strains. Although its market presence is relatively niche compared to broad-spectrum antibiotics, ongoing concerns surrounding antimicrobial resistance (AMR) influence its market dynamics and investment potential. This report analyzes the key factors shaping the market for nafcilin sodium, assesses its financial trajectory, and offers strategic insights for stakeholders.

Market Overview

Global Market Size and Segmentation

The global antibiotic market, projected to reach over USD 50 billion by 2025 (according to MarketsandMarkets), encompasses various classes, including beta-lactams, macrolides, and aminoglycosides. Nafcillin sodium, classified within the beta-lactam subgroup, represents a small yet steady segment primarily within North American and European markets, where hospital-acquired infections (HAIs) caused by penicillinase-producing Staphylococcus aureus (S. aureus) are prevalent.

The drug is primarily available through intravenous formulations, prescribed for skin and soft tissue infections, osteomyelitis, and endocarditis caused by methicillin-sensitive S. aureus (MSSA). While generic versions dominate supply, newer formulations and absence of patent protections sustain steady demand in hospital settings.

Regional Market Dynamics

• North America: The dominant market due to high prevalence of MRSA/MSSA infections and well-established healthcare infrastructure. The U.S. consumes a majority of nafcilin sodium, with hospitals emphasizing antimicrobial stewardship programs reducing unnecessary antibiotic use but maintaining essential usage for resistant infections [2].

• Europe: Similar to North America, with pharmacovigilance and resistance trends influencing formularies. European Union regulations and guidelines affect prescribing patterns, maintaining stable demand for targeted antibiotics like nafcilin sodium.

• Asia-Pacific: Growing economic development and rising infection rates expand the potential market. However, regulatory heterogeneity and healthcare infrastructure disparities challenge uniform adoption.

Market Drivers and Challenges

Drivers

• Rising AMR and Resistant Strains: Increased resistance among S. aureus strains elevates demand for beta-lactamase-resistant antibiotics like nafcilin.
• Hospital-Acquired Infections: The surge in HAIs attributable to resistant bacteria sustains steady prescription of nafcilin sodium.
• Limited Alternatives: In settings where MRSA/mSSA infections are prevalent, nafcilin remains a preferred choice owing to efficacy and safety profile.

Challenges

• Emergence of New Antibiotics: Novel agents, such as ceftaroline and delafloxacin, offer alternatives, potentially encroaching on nafcilin's market share.
• Antibiotic Stewardship Policy: Enhanced regulations to curb antibiotic misuse could reduce overall demand.
• Patent and Generic Competition: Most formulations are off-patent, exerting price and profit pressures.

Regulatory and Patent Landscape

Most nafcilin sodium formulations are off-patent, with numerous generic manufacturers. This fosters price competition but limits lucrative exclusivity. Regulatory requirements for hospital approval are standardized but rigorous, requiring ongoing safety and efficacy data, especially as newer antibiotics emerge.

Financial Trajectory and Investment Outlook

Historical Revenue Trends

Given its niche market, nafcilin sodium historically accounts for hundreds of millions USD globally, primarily in the hospital procurement sector. The market has been relatively stable over the past decade, with minor fluctuations driven by infection rates, resistance patterns, and healthcare policies [1].

Forecasted Growth

Analysts project a modest compound annual growth rate (CAGR) of approximately 2-3% over the next five years, primarily driven by the increasing burden of resistant bacterial infections. The growth is constrained by generic competition and shifting prescribing habits [3].

Profitability Prospects

Profit margins for nafcilin sodium are likely narrow due to high generic competition and hospital procurement cost pressures. However, niche positioning within antimicrobial stewardship programs ensures a resilient baseline. Companies with efficient manufacturing and supply chain operations can maintain profitability.

Potential Disruptors

• Emerging Resistance: Increasing resistance reduces clinical efficacy, possibly leading to regulatory restrictions.
• Innovative Therapies: Advances in bacteriophage therapy or new antibiotics may displace nafcilin in certain indications.
• Market Consolidation: Mergers and acquisitions can influence pricing strategies and market access.

Investment Considerations

Investors should weigh the drug's essential role against limited growth prospects. Companies invested in niche antibiotics can benefit from hospital procurement channels and resistance-driven demand. Conversely, innovation-driven biotech firms may seek to replace older agents like nafcilin with novel therapeutics offering higher margins and patent protections.

Strategic Outlook

Pharmaceutical companies should leverage antimicrobial stewardship initiatives to ensure continued use where clinically justified. Optimization of production efficiencies and strategic partnerships with hospitals can fortify market position. Continued surveillance of resistance patterns and regulatory developments must inform R&D investments.

Conclusion

Nafcillin sodium remains an important antimicrobial within specialized hospital settings, especially for MSSA infections. Its market is characterized by steady demand, constrained by generic competition and evolving resistance patterns. Financially, it offers stable, albeit modest, profitability with limited growth but considerable strategic value in antimicrobial stewardship. Stakeholders should focus on operational efficiencies and vigilant regulatory monitoring to sustain its market presence.

Key Takeaways

• The nafcilin sodium market remains niche but stable, driven by resistance trends and hospital needs.
• Generic competition limits profit margins; innovation or formulations with improved safety may present opportunities.
• Increasing antimicrobial resistance sustains demand but challenges include emerging alternatives and regulation.
• Strategic positioning within hospital formularies and stewardship programs enhances long-term viability.
• Investors and companies should monitor resistance surveillance and regulatory trajectories to adapt strategies.

FAQs

1. What are the primary clinical indications for nafcilin sodium?
Nafcillin sodium is primarily indicated for treating methicillin-sensitive S. aureus (MSSA) infections, including skin and soft tissue infections, osteomyelitis, and endocarditis.

2. How does resistance impact the market for nafcilin sodium?
Rising resistance among bacterial strains can both increase demand for targeted agents like nafcilin but also pose a threat if resistant strains develop beyond nafcilin's efficacy, leading to reduced utilization.

3. Are there generic versions of nafcilin sodium available?
Yes, numerous manufacturers produce generic nafcilin sodium formulations, intensifying price competition and constraining margins.

4. What are potential growth opportunities for nafcilin sodium?
Growth opportunities include targeted use in resistant infections, potential formulation innovations, and expanding hospital market penetration through stewardship programs.

5. How might regulatory changes influence nafcilin sodium's market?
Stricter antimicrobial stewardship policies could limit overall antimicrobial use, including nafcilin sodium, while favorable regulations for hospital-approved antibiotics can maintain or boost demand.

---

Sources:

[1] MarketsandMarkets. “Antibiotics Market by Type, Application, and Region,” 2020.
[2] CDC. “Antimicrobial Resistance Threats in the United States,” 2019.
[3] Global Data. “Antibiotic Market Forecast,” 2021.